Modality
Gene Editing
MOA
Anti-Aβ
Target
BET
Pathway
PD-1/PD-L1
OCD
Development Pipeline
Preclinical
~Nov 2018
→ ~Feb 2020
Phase 1
~May 2020
→ ~Aug 2021
Phase 2
~Nov 2021
→ ~Feb 2023
Phase 3
~May 2023
→ ~Aug 2024
NDA/BLA
Nov 2024
NDA/BLACurrent
NCT08366114
788 pts·OCD
2024-11→TBD·Completed
788 total pts1 indication
Approved
CompletedCurrentUpcoming
Trial Timeline
NDA/BLA
Complet…
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08366114 | NDA/BLA | OCD | Completed | 788 | FEV1 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-5767 | Pfizer | Phase 1/2 | BET | |
| LLY-8369 | Eli Lilly | Approved | Menin | |
| RHH-1969 | Roche | Approved | BET | |
| NVS-5439 | Novartis | Preclinical | BET | |
| ABB-8696 | AbbVie | Phase 3 | BCMA | |
| Ivocapivasertib | Bristol-Myers Squibb | Phase 1 | BET | |
| BAY-6035 | Bayer | Phase 1 | C5 | |
| Zenotinib | BioNTech | Phase 1 | CGRP | |
| Adagracapivasertib | BeiGene | NDA/BLA | BET | |
| 207-5197 | Samsung Biologics | Approved | BET |